Hou De Zhou, M.D., Postdoctoral fellow, Duke University, USA; Currently, he is a professor and doctoral supervisor of the Second Xiangya Hospital of Central South University, Deputy director of the National Clinical Medical Research Center for Metabolic Diseases, director of the Key Laboratory of Metabolic Bone Disease of Hunan Province, and director of the Laboratory of Genetic Endocrinology and Metabolic Diseases of the Second Xiangya Hospital. Standing Committee and Vice Chairman of Hunan Science and Technology Association; Member of the Standing Committee of Diabetes Prevention and Control Committee, Chinese Society for Preventive Medicine; Deputy Chairman of Endocrinology Expert Committee, Osteoporosis Branch, Chinese Gerontology and Geriatric Society; Chairman of the Osteoporosis Prevention and Control Committee and Deputy Chairman of the Obesity Prevention and Control Committee of Hunan Preventive Medical Association; He is a member of the basic group of Endocrinology Professional Committee of Chinese Medical Association, a leader of high-level health talents in Hunan Province, a winner of the 7th Hunan Youth Science and Technology Award, a candidate of Hunan Provincial Science and Technology Leading Talents Plan. He has conducted research on more than 20 large-scale projects such as the National Science and Technology Support Plan, the National Natural Science Foundation, major science and technology projects of the Ministry of Education, and major science and technology projects of Hunan Province.
Clinical and basic research on metabolic diseases such as osteoporosis, obesity and diabetes, as well as corresponding product transformation research; Won 1 second prize of National Science and Technology Progress, 2 first prize of Hunan Province Science and Technology Progress, and 8 other provincial and ministerial awards; 5 national invention patents, 1 international patent, 2 achievements transformation; He has presided over 8 National Natural Science Foundation projects, more than 20 other national and provincial projects, and published more than 100 SCI papers. He is mainly engaged in the research of metabolic bone disease, obesity and genetic metabolic disease. New bone remodeling molecules have been discovered to clarify the new mechanism of osteoporosis, and new products have been developed and related clinical applications have been carried out. He invented the bone reconstruction theory based on collagen collagen and its hydrolyzed small molecules, discovered and named a new collagen active peptide ACP-1 and obtained an international patent, and prepared an in vitro detection kit for ACP-1, which proved its good clinical application value as in vitro diagnosis and efficacy monitoring of osteoporosis, and signed a contract with Hunan Kangrun Pharmaceutical for industrialization. Currently preparing to apply for medical device registration certificate. The first accurate evaluation and prevention system of obesity and its metabolic complications, the invention and preparation of obesity inhibitor peptide and simple visceral obesity measuring instrument; Developed an intelligent whole-process individualized prevention and treatment system for obesity and its metabolic complications -- "DejiaoShou" (which can be accessed through wechat to find the mini program Dejiaoshou), realized accurate assessment of individual metabolic risks, and developed individualized intelligent diet prescription and exercise prescription systems; The invention of a human anti-obesity peptide, obtained the national invention patent and successfully realized the patent transfer transformation; It was found that hyperglycemia and impaired blood glucose balance caused by obesity were risk factors for severe COVID-19. The convenient body surface diameter measuring instrument (which has been applied for national invention patent) was invented and used for simple assessment of visceral obesity. The cutting point value of body surface diameter in the diagnosis of visceral obesity in Chinese people of different genders was determined, and it was found that the diagnosis of metabolic syndrome was more accurate than body mass index, waist circumference, etc., which is expected to be widely applied in the whole society. The precise diagnosis system of a variety of genetic endocrine and metabolic diseases was first established, and an individualized treatment scheme based on accurate diagnosis was established. It was the first to build and apply the preliminary screening model and standard diagnosis system for the diagnosis of hereditary glycolipid metabolic diseases, providing a reference database for the genetic diagnosis of hereditary glycolipid metabolic diseases in China for clinical diagnosis, and has been extended to nearly 20 hospitals in more than 10 provinces. For the first time in the world, the pathogenic sites or clinical phenotypes of a variety of inherited glycolipid metabolic diseases have been identified, which has realized the accurate diagnosis of some inherited glycolipid metabolic diseases in China, and carried out individualized treatment after accurate diagnosis, and achieved good therapeutic effects. In the application unit, the diagnosis rate of hereditary glycolipid metabolic diseases has been effectively improved, which has not only brought economic benefits, but also produced a good social impact.